Form 4: Adaptive Biotechnologies CEO Chad Robins Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Chad Robins, CEO and Chairman of Adaptive Biotechnologies, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Chad Robins, the CEO and Chairman of Adaptive Biotechnologies, executed stock options to acquire common stock at a price of $6.32 per share.
- He then sold these shares on the open market at weighted average prices ranging from $8.44 to $8.50.
- These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 26, 2024.
- On February 13, 2025, Robins acquired and disposed of 100,287 shares.
- On February 14, 2025, Robins acquired and disposed of 158,921 shares.
- On February 18, 2025, Robins acquired and disposed of 211,160 shares.
- Following these transactions, Robins directly owns 2,576,701 shares of common stock.
- He also holds options to purchase 285,187 shares of common stock, which expire on June 9, 2025.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or performance. It is common for executives to use 10b5-1 plans to diversify their holdings and avoid accusations of trading on inside information.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across the biotechnology industry.
- Comparing Adaptive Biotechnologies' executive compensation structure and insider trading activity to peers like Illumina (ILMN) or Guardant Health (GH) would provide a broader context.
- The use of Rule 10b5-1 trading plans is a standard practice among public company executives to manage their stock holdings.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| August 26, 2024 | Date the reporting person adopted a Rule 10b5-1 trading plan |
| February 13, 2025 | Date of first reported transaction: exercise of options and sale of shares |
| February 14, 2025 | Date of second reported transaction: exercise of options and sale of shares |
| February 18, 2025 | Date of third reported transaction: exercise of options and sale of shares |
| June 9, 2025 | Expiration date of the stock options |
Keywords
Adaptive Biotechnologies, Chad Robins, stock options, Rule 10b5-1, insider trading, ADPT, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.